{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:07:43Z","timestamp":1781582863091,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,8]]},"DOI":"10.7759\/cureus.28946","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T19:32:30Z","timestamp":1662665550000},"source":"Crossref","is-referenced-by-count":8,"title":["The Risk of Fatal Arrhythmias Associated With Sertraline in Patients With Post-myocardial Infarction Depression"],"prefix":"10.7759","author":[{"given":"Sai Dheeraj","family":"Gutlapalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerthana","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran Maee","family":"Swarnakari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohana Priya","family":"Manoharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabab","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneeque","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Csendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darshi M","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Alfonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960200304","article-title":"Depression and coronary heart disease: a review for cardiologists","volume":"20","author":"Carney RM","year":"1997","unstructured":"Carney RM, Freedland KE, Sheline YI, Weiss ES. Depression and coronary heart disease: a review for cardiologists. Clin Cardiol. 1997, 20:196-200. 10.1002\/clc.4960200304","journal-title":"Clin Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2010.513701","article-title":"Management of depression in patients with coronary heart disease: association, mechanisms, and treatment implications for depressed cardiac patients","volume":"12","author":"Wang JT","year":"2011","unstructured":"Wang JT, Hoffman B, Blumenthal JA. Management of depression in patients with coronary heart disease: association, mechanisms, and treatment implications for depressed cardiac patients. Expert Opin Pharmacother. 2011, 12:85-98. 10.1517\/14656566.2010.513701","journal-title":"Expert Opin Pharmacother"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.831359","article-title":"Psychological and psychopharmacological interventions in psychocardiology","volume":"13","author":"Kahl KG","year":"2022","unstructured":"Kahl KG, Stapel B, Correll CU. Psychological and psychopharmacological interventions in psychocardiology. Front Psychiatry. 2022, 13:1-11. 10.3389\/fpsyt.2022.831359","journal-title":"Front Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2003.015230","article-title":"Heart and mind: (2) psychotropic and cardiovascular therapeutics","volume":"81","author":"Shah SU","year":"2005","unstructured":"Shah SU, Iqbal Z, White A, White S. Heart and mind: (2) psychotropic and cardiovascular therapeutics. Postgrad Med J. 2005, 81:33-40. 10.1136\/pgmj.2003.015230","journal-title":"Postgrad Med J"},{"key":"ref5","article-title":"Depression and coronary artery disease: the association, mechanisms, and therapeutic implications","volume":"6","author":"Khawaja IS","year":"2009","unstructured":"Khawaja IS, Westermeyer JJ, Gajwani P, Feinstein RE. Depression and coronary artery disease: the association, mechanisms, and therapeutic implications. Psychiatry. 2009, 6:38-51.","journal-title":"Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3205\/000194","article-title":"Position paper on the importance of psychosocial factors in cardiology: update 2013","volume":"12","author":"Ladwig KH","year":"2014","unstructured":"Ladwig KH, Lederbogen F, Albus C, et al.. Position paper on the importance of psychosocial factors in cardiology: update 2013. Ger Med Sci. 2014, 12:Doc09. 10.3205\/000194","journal-title":"Ger Med Sci"},{"key":"ref7","article-title":"Cardiovascular considerations in antidepressant therapy: an evidence-based review","volume":"8","author":"Yekehtaz H","year":"2013","unstructured":"Yekehtaz H, Farokhnia M, Akhondzadeh S. Cardiovascular considerations in antidepressant therapy: an evidence-based review. J Tehran Heart Cent. 2013, 8:169-76.","journal-title":"J Tehran Heart Cent"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S200360","article-title":"Cardiac dysautonomia in depression - heart rate variability biofeedback as a potential add-on therapy","volume":"15","author":"Pinter A","year":"2019","unstructured":"Pinter A, Szatmari S Jr, Horvath T, Penzlin AI, Barlinn K, Siepmann M, Siepmann T. Cardiac dysautonomia in depression - heart rate variability biofeedback as a potential add-on therapy. Neuropsychiatr Dis Treat. 2019, 15:1287-310. 10.2147\/NDT.S200360","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2002.4.1\/pschulz","article-title":"The clinical pharmacology of depressive states","volume":"4","author":"Schulz P","year":"2002","unstructured":"Schulz P, Macher JP. The clinical pharmacology of depressive states. Dialogues Clin Neurosci. 2002, 4:47-56. 10.31887\/DCNS.2002.4.1\/pschulz","journal-title":"Dialogues Clin Neurosci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/HRP.0000000000000162","article-title":"Depression and anxiety in heart failure: a review","volume":"26","author":"Celano CM","year":"2018","unstructured":"Celano CM, Villegas AC, Albanese AM, Gaggin HK, Huffman JC. Depression and anxiety in heart failure: a review. Harv Rev Psychiatry. 2018, 26:175-84. 10.1097\/HRP.0000000000000162","journal-title":"Harv Rev Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.13r01511","article-title":"Diagnosis and treatment of depression in patients with congestive heart failure: a review of the literature","volume":"15","author":"Rustad JK","year":"2013","unstructured":"Rustad JK, Stern TA, Hebert KA, Musselman DL. Diagnosis and treatment of depression in patients with congestive heart failure: a review of the literature. Prim Care Companion CNS Disord. 2013, 15:10.4088\/PCC.13r01511","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2014.05.002","article-title":"A systematic approach to pharmacotherapy for geriatric major depression","volume":"30","author":"Mulsant BH","year":"2014","unstructured":"Mulsant BH, Blumberger DM, Ismail Z, Rabheru K, Rapoport MJ. A systematic approach to pharmacotherapy for geriatric major depression. Clin Geriatr Med. 2014, 30:517-34. 10.1016\/j.cger.2014.05.002","journal-title":"Clin Geriatr Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3109\/00048674.2011.595686","article-title":"A consensus statement for safety monitoring guidelines of treatments for major depressive disorder","volume":"45","author":"Dodd S","year":"2011","unstructured":"Dodd S, Malhi GS, Tiller J, et al.. A consensus statement for safety monitoring guidelines of treatments for major depressive disorder. Aust NZ J Psychiatry. 2011, 45:712-25. 10.3109\/00048674.2011.595686","journal-title":"Aust NZ J Psychiatry"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.s6880","article-title":"The relationship between depression, anxiety, and cardiovascular outcomes in patients with acute coronary syndromes","volume":"6","author":"Huffman JC","year":"2010","unstructured":"Huffman JC, Celano CM, Januzzi JL. The relationship between depression, anxiety, and cardiovascular outcomes in patients with acute coronary syndromes. Neuropsychiatr Dis Treat. 2010, 6:123-36. 10.2147\/ndt.s6880","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5455\/msm.2019.31.110-114","article-title":"Depression in survivors of acute myocardial infarction","volume":"31","author":"Trajanovska AS","year":"2019","unstructured":"Trajanovska AS, Kostov J, Perevska Z. Depression in survivors of acute myocardial infarction. Mater Sociomed. 2019, 31:110-4. 10.5455\/msm.2019.31.110-114","journal-title":"Mater Sociomed"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.05.003","article-title":"Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure","volume":"156","author":"Jiang W","year":"2008","unstructured":"Jiang W, O'Connor C, Silva SG, et al.. Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure. Am Heart J. 2008, 156:437-44. 10.1016\/j.ahj.2008.05.003","journal-title":"Am Heart J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018686","article-title":"Psychiatric and psychological interventions for depression in patients with heart disease: a scoping review","volume":"9","author":"Zambrano J","year":"2020","unstructured":"Zambrano J, Celano CM, Januzzi JL, Massey CN, Chung WJ, Millstein RA, Huffman JC. Psychiatric and psychological interventions for depression in patients with heart disease: a scoping review. J Am Heart Assoc. 2020, 9:e018686. 10.1161\/JAHA.120.018686","journal-title":"J Am Heart Assoc"},{"key":"ref18","article-title":"Comparison of the effects of religious cognitive behavioral therapy (RCBT), cognitive behavioral therapy (CBT), and sertraline on depression and anxiety in patients after coronary artery bypass graft surgery: study protocol for a randomized controlled trial","volume":"12","author":"Hosseini SH","year":"2017","unstructured":"Hosseini SH, Rafiei A, Gaemian A, et al.. Comparison of the effects of religious cognitive behavioral therapy (RCBT), cognitive behavioral therapy (CBT), and sertraline on depression and anxiety in patients after coronary artery bypass graft surgery: study protocol for a randomized controlled trial. Iran J Psychiatry. 2017, 12:206-13.","journal-title":"Iran J Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.12659\/msm.881924","article-title":"Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis","volume":"17","author":"Wozniak G","year":"2011","unstructured":"Wozniak G, Toska A, Saridi M, Mouzas O. Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis. Med Sci Monit. 2011, 17:RA205-14. 10.12659\/msm.881924","journal-title":"Med Sci Monit"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2009.03.004","article-title":"Serotonin transporter polymorphisms, microstructural white matter abnormalities and remission of geriatric depression","volume":"119","author":"Alexopoulos GS","year":"2009","unstructured":"Alexopoulos GS, Murphy CF, Gunning-Dixon FM, et al.. Serotonin transporter polymorphisms, microstructural white matter abnormalities and remission of geriatric depression. J Affect Disord. 2009, 119:132-41. 10.1016\/j.jad.2009.03.004","journal-title":"J Affect Disord"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2013.03.001","article-title":"Psychological distress and arrhythmia: risk prediction and potential modifiers","volume":"55","author":"Peacock J","year":"2013","unstructured":"Peacock J, Whang W. Psychological distress and arrhythmia: risk prediction and potential modifiers. Prog Cardiovasc Dis. 2013, 55:582-9. 10.1016\/j.pcad.2013.03.001","journal-title":"Prog Cardiovasc Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2012.00076","article-title":"Sudden death of cardiac origin and psychotropic drugs","volume":"3","author":"Timour Q","year":"2012","unstructured":"Timour Q, Frassati D, Descotes J, Chevalier P, Christ\u00e9 G, Chahine M. Sudden death of cardiac origin and psychotropic drugs. Front Pharmacol. 2012, 3:76. 10.3389\/fphar.2012.00076","journal-title":"Front Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2016.08.037","article-title":"The impact of treatment with selective serotonin reuptake inhibitors on primate cardiovascular disease, behavior, and neuroanatomy","volume":"74","author":"Shively CA","year":"2017","unstructured":"Shively CA, Silverstein-Metzler M, Justice J, Willard SL. The impact of treatment with selective serotonin reuptake inhibitors on primate cardiovascular disease, behavior, and neuroanatomy. Neurosci Biobehav Rev. 2017, 74:433-43. 10.1016\/j.neubiorev.2016.08.037","journal-title":"Neurosci Biobehav Rev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint13030038","article-title":"Selective serotonin reuptake inhibitors and adverse effects: a narrative review","volume":"13","author":"Edinoff AN","year":"2021","unstructured":"Edinoff AN, Akuly HA, Hanna TA, et al.. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int. 2021, 13:387-401. 10.3390\/neurolint13030038","journal-title":"Neurol Int"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i1350","article-title":"Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database","volume":"352","author":"Coupland C","year":"2016","unstructured":"Coupland C, Hill T, Morriss R, Moore M, Arthur A, Hippisley-Cox J. Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database. BMJ. 2016, 352:i1350. 10.1136\/bmj.i1350","journal-title":"BMJ"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006117.pub4","article-title":"Sertraline versus other antidepressive agents for depression","volume":"2010","author":"Cipriani A","year":"2010","unstructured":"Cipriani A, La Ferla T, Furukawa TA, et al.. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2010, 2010:CD006117. 10.1002\/14651858.CD006117.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2001.tb00188.x","article-title":"The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders","volume":"7","author":"MacQueen G","year":"2001","unstructured":"MacQueen G, Born L, Steiner M. The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev. 2001, 7:1-24. 10.1111\/j.1527-3458.2001.tb00188.x","journal-title":"CNS Drug Rev"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12742","article-title":"A randomized placebo-controlled trial of Omega-3 and sertraline in depressed patients with or at risk for coronary heart disease","volume":"80","author":"Carney RM","year":"2019","unstructured":"Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS. A randomized placebo-controlled trial of Omega-3 and sertraline in depressed patients with or at risk for coronary heart disease. J Clin Psychiatry. 2019, 80:10.4088\/JCP.19m12742","journal-title":"J Clin Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.03.068","article-title":"Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial","volume":"56","author":"O'Connor CM","year":"2010","unstructured":"O'Connor CM, Jiang W, Kuchibhatla M, et al.. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010, 56:692-9. 10.1016\/j.jacc.2010.03.068","journal-title":"J Am Coll Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1487","article-title":"Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial","volume":"302","author":"Carney RM","year":"2009","unstructured":"Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. JAMA. 2009, 302:1651-7. 10.1001\/jama.2009.1487","journal-title":"JAMA"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-1173-2","article-title":"Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis","volume":"17","author":"Jakobsen JC","year":"2017","unstructured":"Jakobsen JC, Katakam KK, Schou A, et al.. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry. 2017, 17:58. 10.1186\/s12888-016-1173-2","journal-title":"BMC Psychiatry"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00763-z","article-title":"The cardiovascular effects of newer antidepressants in older adults and those with or at high risk for cardiovascular diseases","volume":"34","author":"Behlke LM","year":"2020","unstructured":"Behlke LM, Lenze EJ, Carney RM. The cardiovascular effects of newer antidepressants in older adults and those with or at high risk for cardiovascular diseases. CNS Drugs. 2020, 34:1133-47. 10.1007\/s40263-020-00763-z","journal-title":"CNS Drugs"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/01.JCN.0000338929.89210.af","article-title":"Depression treatment with selective serotonin reuptake inhibitors for the postacute coronary syndrome population: a literature review","volume":"23","author":"Regan KL","year":"2008","unstructured":"Regan KL. Depression treatment with selective serotonin reuptake inhibitors for the postacute coronary syndrome population: a literature review. J Cardiovasc Nurs. 2008, 23:489-96. 10.1097\/01.JCN.0000338929.89210.af","journal-title":"J Cardiovasc Nurs"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001875","article-title":"Association between common cardiovascular drugs and depression","volume":"134","author":"Tao SH","year":"2021","unstructured":"Tao SH, Ren XQ, Zhang LJ, Liu MY. Association between common cardiovascular drugs and depression. Chin Med J. 2021, 134:2656-65. 10.1097\/CM9.0000000000001875","journal-title":"Chin Med J"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1159\/000486794","article-title":"Antidepressant use by class: association with major adverse cardiac events in patients with coronary artery disease","volume":"87","author":"Grace SL","year":"2018","unstructured":"Grace SL, Medina-Inojosa JR, Thomas RJ, Krause H, Vickers-Douglas KS, Palmer BA, Lopez-Jimenez F. Antidepressant use by class: association with major adverse cardiac events in patients with coronary artery disease. Psychother Psychosom. 2018, 87:85-94. 10.1159\/000486794","journal-title":"Psychother Psychosom"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2147\/JEP.S209085","article-title":"The effect of sertraline on hemodynamic parameters and nitric oxide production in isolated rat hearts subjected to ischemia and reperfusion","volume":"11","author":"Grotthus B","year":"2019","unstructured":"Grotthus B, Szel\u0105g A. The effect of sertraline on hemodynamic parameters and nitric oxide production in isolated rat hearts subjected to ischemia and reperfusion. J Exp Pharmacol. 2019, 11:149-58. 10.2147\/JEP.S209085","journal-title":"J Exp Pharmacol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013394","article-title":"Antidepressants for major depression disorder in older people: a network meta\u2010analysis","volume":"2019","author":"Robertson L","year":"2019","unstructured":"Robertson L, Bertolini F, Meader N, Davies SJ, Barbui C, Gilbody S, Churchill R. Antidepressants for major depression disorder in older people: a network meta\u2010analysis. Cochrane Database Syst Rev. 2019, 2019:CD013394. 10.1002\/14651858.CD013394","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/110761-the-risk-of-fatal-arrhythmias-associated-with-sertraline-in-patients-with-post-myocardial-infarction-depression","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:46:56Z","timestamp":1707508016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/110761-the-risk-of-fatal-arrhythmias-associated-with-sertraline-in-patients-with-post-myocardial-infarction-depression"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,8]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.28946","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,8]]}}}